Edgaras Zaboras

Mr. Edgaras Zaboras

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ADAurelija Daškevičiūtė
Aurelija Daškevičiūtė
Edgaras ZaborasEdgaras Zaboras
Edgaras Zaboras
JNJonas Navalinskas
Jonas Navalinskas
KBKarolis Baronas
Karolis Baronas
AJArminas Jasionis
Arminas Jasionis
RMRuta Mameniskiene
Ruta Mameniskiene
The most investigated ABCB1 single-nucleotide polymorphisms (SNPs) related to antiseizure medication resistance are rs1045642 (c.3435C>T, p.Ile1145=), rs2032582 (c.2677G>T/A, p.Ala893Ser/Thr), and rs1128503 (c.1236C>T, p.Gly412=). We conducted a literature review to evaluate the genotype frequencies of rs1045642, rs2032582, and rs1128503 SNPs in different ancestries among the drug-resistant and drug-responsive epilepsy groups. Furthermore, we performed effect size and study power analyses and determined the expected sample size to reach a study power of 0.8 for each conducted research. High and very high statistical power for the rs1045642, rs2032582, and rs1128503 polymorphisms was achieved in 58.0, 60.7, and 31.8% of the studies, respectively. The effect sizes (ES) of rs1045642, rs2032582, and rs1128503 ranged from 0.03–1.04, 0.06–0.92, and 0.04–0.64, respectively. The required sample sizes for rs1045642, rs2032582, and rs1128503 ranged from 9–13,000, 12–2600, and 24–5700 participants, respectively. None of the polymorphisms showed a statistically significant association with antiseizure medication resistance in the forest plots. Our analysis provides valuable guidance for future genetic association studies in the field of drug-resistant epilepsy.

6 May 2026 in European Stroke Journal
Verified
Journal Article
Open access
Rytis MasiliūnasRytis Masiliūnas
Rytis Masiliūnas
Edgaras ZaborasEdgaras Zaboras
Edgaras Zaboras
VŠVitalija Šumskienė
Vitalija Šumskienė
KJKristaps Jurjāns
Kristaps Jurjāns
JKJanika Kõrv
Janika Kõrv
Aleksandras VilionskisAleksandras Vilionskis
Aleksandras Vilionskis
Introduction: Although epidemiological studies often group the Baltic states together, they differ significantly in national stroke care legislation and infrastructure. Our study aimed to explore and compare the current state of stroke care in Lithuania, Latvia and Estonia. Patients and methods: We analysed the Stroke Action Plan for Europe (SAP-E) Stroke Service Tracker data from 2022, including data from the respective National Health Insurance Funds and direct centre-level queries. Geographic Information System-based modelling assessed population access to stroke-ready hospitals within 1 h. Key metrics, including hospitalised stroke incidence, stroke unit admission, recanalisation therapy and in-hospital as well as 30-day mortality, were compared using Z-tests for proportions. Results: The hospitalised stroke incidence per 100,000 inhabitants was similar in Lithuania (353) and Latvia (354), but lower in Estonia (246), despite similar population structures. Lithuania had the highest proportion of its population (94.0%) with access to a stroke-ready hospital within 1 h, followed by Latvia (87.1%) and Estonia (84.7%, P < .001). Estonia had the highest proportion of stroke unit admission rates and the lowest mortality rates—9.6% (in-hospital) and 15.0% (30-day) for ischaemic stroke. Endovascular treatment was most frequent in Lithuania (8.6% of all strokes, P < .001), while Estonia had the highest rate of intravenous thrombolysis (29.0%, P < .001). Conclusions: Despite broadly comparable populations and formal SAP-E alignment, the Baltic states exhibit marked differences in stroke access, treatment and outcomes. High stroke unit admissions and high recanalisation rates in Estonia may be associated with lower ischaemic stroke mortality, underscoring the importance of system design beyond geographic coverage alone.

29 May 2026 in PLOS ONE
Verified
Journal Article
Open access
IKIeva Kubiliute
Ieva Kubiliute
Edgaras ZaborasEdgaras Zaboras
Edgaras Zaboras
FMFausta Majauskaite
Fausta Majauskaite
JUJurgita Urboniene
Jurgita Urboniene
BZBirute Zablockiene
Birute Zablockiene
LJLigita Jancoriene
Ligita Jancoriene
Background: Since its emergence, the COVID-19 infection has led to significant morbidity and mortality worldwide. Early identification of patients at risk for severe disease is essential for more effective triage, timely therapeutic intervention, and optimal resource allocation. Differences in population characteristics may contribute to variability in disease outcomes, which emphasizes the need for regional-level data, especially from underrepresented regions. The main aim of this study was to identify the demographic, clinical, and laboratory predictors of severe COVID-19, defined as the need for oxygen therapy, in Lithuania. Materials and methods: We conducted an ambispective observational cohort study at Vilnius University Hospital Santaros Klinikos in Vilnius, Lithuania, from March 2020 to December 2021. Adult patients with a confirmed diagnosis of COVID-19 and hospitalized longer than 24 hours were included in this study. Data were collected from the electronic medical records and patient interviews. To identify predictors of severe COVID-19 course, a multivariable binary logistic regression model was performed. Results: Among 495 patients, 52.9% were male, the median age was 55 years, and 61.2% had at least one underlying condition. The most common symptoms on admission were malaise (77.1%), subfebrile fever (65.9%), and cough (69.7%). CRP demonstrated the highest predictive value for severe COVID-19 (AUC = 0.84), followed by LDH (AUC = 0.80). Older age (OR 1.04 per year, 95% CI 1.00–1.08), obesity (OR 3.55, 95% CI 1.35–9.30), lymphopenia (OR 3.70, 95% CI 1.37–9.99), higher LDH (OR 1.008, 95% CI 1.00–1.01) and CRP (OR 1.021, 95% CI 1.01–1.04) levels were identified as the strongest predictors for severe COVID-19 disease course. Conclusion: Older age, obesity, lymphopenia, and higher CRP and LDH were associated with developing severe COVID-19 disease, indicating that combining patient history and laboratory parameters can provide a practical risk stratification approach to help clinicians identify high-risk patients early upon hospitalisation.

17 February 2026 in Forensic Science, Medicine and Pathology
Verified
Journal Article
Closed access
PDF file
EVEglė Valčiukaitė
Eglė Valčiukaitė
Edgaras ZaborasEdgaras Zaboras
Edgaras Zaboras
ASAndrej Suchomlinov
Andrej Suchomlinov
Dario Piombino-MascaliDario Piombino-Mascali
Dario Piombino-Mascali

1 January 2026 in Acta Neurologica Scandinavica
Verified
Journal Article
Open access
Rytis MasiliūnasRytis Masiliūnas
Rytis Masiliūnas
Edgaras ZaborasEdgaras Zaboras
Edgaras Zaboras
ADAurelija Daškevičiūtė
Aurelija Daškevičiūtė
KJKristaps Jurjāns
Kristaps Jurjāns
JKJanika Kõrv
Janika Kõrv
Aleksandras VilionskisAleksandras Vilionskis
Aleksandras Vilionskis
Background: Stroke remains a major public health challenge in Europe with regional disparities. Although the Baltic states share similar demographic and socioeconomic profiles, they differ in stroke care networks and treatment infrastructure. To date, no direct cross‐country comparison of stroke care has been published. Methods: We conducted a multicenter cross‐sectional analysis of ischemic stroke patients, prospectively recorded in the Registry of Stroke Care Quality (RES‐Q) by 23 of 26 primary and comprehensive stroke centers across the Baltic states during at least 1 month of the first quarter of 2022. Data on demographic characteristics, stroke risk factors, acute management, and discharge destinations were compared with assess intercountry differences. Results: A total of 897 ischemic stroke patients were analyzed: 479 from Lithuania, 294 from Latvia, and 124 from Estonia. Although atrial fibrillation (AF) rates were uniformly high (overall 37.2%), anticoagulant use at stroke onset among patients with known AF was significantly higher in Estonia (72.7%) compared with Latvia (34.9%) and Lithuania (48.8%, p = 0.032). Estonia reported the highest intravenous thrombolysis (IVT) rates (44.4%), whereas Lithuania achieved the highest endovascular treatment (EVT) rates (17.7%). In contrast, Latvia had the lowest recanalization therapy rates (IVT 21.1%, EVT 5.1%). Rehabilitation access varied strikingly: Only 2.7% of Latvian patients were transferred to inpatient rehabilitation compared with 30.5% in Lithuania and 20.2% in Estonia ( p < 0.001). Conclusions: This first comprehensive comparison of stroke care in the Baltic states highlights a high AF burden and important disparities in recanalization therapy and poststroke rehabilitation pathways. Data Access Statement: The data supporting this study′s findings are available from the corresponding author upon reasonable request.